Cost effectiveness results of Early KRAS testing in high risk patients that would have no access to well-timed KRAS testing if they develop metastatic disease.

ICER of cetuximab+FOLFOX vs bevacizumab+FOLFOX is lower than that of cetuximab+FOLFOX vs FOLFOX due to the limited advantage of bevacizumab+FOLFOX on FOLFOX. Differential cost of cetuximab+FOLFOX vs bevacizumab+FOLFOX is minimal whereas efficacy favours cetuximab+FOLFOX on FOLFOX.